[ad_1]
GlaxoSmithKline and Sanofi will begin testing the protein-based COVID vaccine in humans for the first time, following the promising results of previous studies.
The vaccine developed by London-based GSK and Paris-based Sanofi combines existing technology used by Sanofi for the flu vaccine, along with a GSK supplement, known as an adjuvant, which can be mixed with a vaccine. to trigger a stronger immune response, according to Mediafax.
The companies said the clinical trial, which involves 440 healthy adults in the US, was designed to assess the safety and immune response of the vaccine and they expect the first results to be available in December 2020.
If the results are positive, a new phase of tests on a larger scale will follow, and its approval could take place in the first half of 2021.
Combined, the two drug companies have the largest vaccine manufacturing capacity in the world and are expanding production to reach 1 billion doses by 2021.
The initiation of a clinical trial was an “important step” toward a possible vaccine that could help defeat COVD-19, said Thomas Triomphe, global director of Sanofi Pasteur.
“Our dedicated teams and partners continue to work 24 hours a day as our goal is to deliver the first results in early December,” he added.
Web Editor: Monica Bonea
